Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor.
Age-related macular degeneration (AMD) complications are the leading cause of severe vision loss among the aging population in the many western countries. The introduction of molecular inhibitors of vascular endothelial growth factor (VEGF), such as pegaptanib, ranibizumab, and bevacizumab, as treatments for wet AMD has provided new hope for affected patients. Now we have these treatment options, which have the possibility to improve or maintain visual acuity for patients suffering from AMD. The treatment needs to be optimized and this is in progress. Based on emerging evidence, adopting a variable VEGF inhibitor-dosing strategy guided by visual acuity assessment and optical coherence tomography are now being tried to reduce the frequency of injections. VEGF inhibitors in combination with photodynamic therapy are another way to optimize treatment. Physicians are waiting for new guidelines for the management of AMD and the results of current and upcoming trials systematically addressing these issues will be expected to provide it.
Sassa
Yukio
Y
Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Hata
Yasuaki
Y
Am J Ophthalmol. 2003 Dec;136(6):1049-61
14644215
Ophthalmology. 2002 Jun;109(6):1092-7
12045049
J BUON. 2008 Jan-Mar;13(1):31-6
18404783
Am J Ophthalmol. 1980 Dec;90(6):810-6
7446668
Arch Ophthalmol. 2004 Apr;122(4):477-85
15078664
Graefes Arch Clin Exp Ophthalmol. 2007 Jul;245(7):941-8
17186262
Adv Ther. 1997 Sep-Oct;14(5):275-80
10174620
Retina. 2006 May-Jun;26(5):495-511
16770255
Surv Ophthalmol. 2000 Sep-Oct;45(2):115-34
11033038
Ophthalmology. 2006 Jun;113(6):992-1001.e6
16647134
N Engl J Med. 2004 Dec 30;351(27):2805-16
15625332
Am J Ophthalmol. 2008 Feb;145(2):239-248
18222192
Retina. 2002 Feb;22(1):6-18
11884872
N Engl J Med. 2006 Oct 5;355(14):1419-31
17021318
Graefes Arch Clin Exp Ophthalmol. 2009 Jul;247(7):899-906
19308441
Biochem Biophys Res Commun. 1998 Nov 27;252(3):743-6
9837777
Arch Ophthalmol. 1984 Nov;102(11):1640-2
6208888
Retina. 2002 Apr;22(2):143-52
11927845
Am J Ophthalmol. 2006 Jul;142(1):1-9
16815245
Invest Ophthalmol Vis Sci. 2003 May;44(5):2141-6
12714654
Invest Ophthalmol Vis Sci. 2005 Jun;46(6):1907-10
15914602
Ophthalmology. 2006 Sep;113(9):1508.e1-25
16828500
Ophthalmology. 2009 Nov;116(11):2175-81.e1
19700194
Invest Ophthalmol Vis Sci. 2005 Feb;46(2):726-33
15671306
J Clin Invest. 2000 Aug;106(4):541-50
10953029
Am J Ophthalmol. 1981 Jun;91(6):785-8
7246702
Am J Ophthalmol. 2007 Apr;143(4):566-83
17386270
Ophthalmology. 2006 Mar;113(3):363-372.e5
16458968
Ophthalmology. 2007 Sep;114(9):1702-12
17509689
Retina. 2009 Apr;29(4):523-9
19262441
Neurosignals. 2005;14(5):207-21
16301836
Ophthalmology. 1997 Jan;104(1):7-21
9022098
N Engl J Med. 2006 Oct 5;355(14):1432-44
17021319
Aust N Z J Ophthalmol. 1995 Nov;23(4):293-8
11980075
Doc Ophthalmol. 2009 Dec;119(3):163-9
20101800
Arch Ophthalmol. 1985 May;103(5):708-11
2581536
Nat Med. 2008 Feb;14(2):194-8
18223656
Arch Ophthalmol. 1992 Aug;110(8):1155-9
1497531
Circulation. 1998 Jan 6-13;97(1):99-107
9443437
Br J Ophthalmol. 2006 Nov;90(11):1344-9
16854824
Acta Ophthalmol. 2008 Jun;86(4):372-6
18028234
Clin Exp Ophthalmol. 2008 Nov;36(8):748-55
19128380
Retina. 2005 Feb-Mar;25(2):119-34
15689800
Arch Ophthalmol. 2001 Feb;119(2):198-207
11176980
Retina. 2007 Apr-May;27(4):439-44
17420695